Dr Asad Qureshi

Oncologist, Consultant Clinical Oncologist , Guy's and St Thomas’ NHS Foundation Trust (GSTT)
  • London, United Kingdom
  • En, En
  • Best at: Upper and lower gastro-intestinal cancers

Dr Asad Qureshi is a Consultant Clinical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust. In his NHS and private practice, he specialises in the treatment of upper and lower gastro-intestinal cancers: Oesophageal Cancer, Stomach Cancer, Colon Cancer, Rectal Cancer, Anal Cancer, Chemotherapy, SABR including CyberKnife. Dr Qureshi is the Clinical Lead for out-patients in the Cancer Centre at Guy’s Hospital, London and is a member of the Senior Oncology Management Team. He is also the Clinical Oncology and Radiotherapy Audit Lead and the Clinical Oncology Oesophago-gastric lead. He trained at St Bartholomew’s and The Royal London Hospitals medical schools where he gained a BSc in neurosciences. He completed his specialist training in Clinical Oncology at a number of specialist departments in London, including Guy’s and St Thomas’ Hospital, Charing Cross Hospital, St Bartholomew’s Hospital and The Royal Marsden Hospital. During his training spent two years working in the Imaging Sciences Laboratories at Kings College London, and the Centre for Medical Image Computing at University College London assessing novel radiotherapy techniques for the treatment of mobile tumours. Dr Qureshi plays an active role in research and is a Principle Investigator on a number of national clinical trials. His research interests include Stereotactic Radiotherapy (SABR), Image-guided Radiotherapy (IGRT) and dose escalation of radiotherapy and he has published a number of papers in this field. Dr Qureshi is committed to medical education. He is a clinical and educational supervisor for Clinical Oncology trainees at Guy’s and St Thomas’ NHS Foundation Trust. He is also a Medical Supervisor for radiographers on prescribing courses.

Statistics.

Achievements of Dr Asad Qureshi

Trustedoctor credentials
-
Clinical endorsements
2
Articles
7
Scientific
co-authors
Trustedoctor credentials
12
General specialty
10
Subspeciality
Languages

About.

Information about Dr Asad Qureshi

Timeline
Place
Country
Position
Focus
2016
University of London
United Kingdom
MD (Res)
2012
The Royal College of Radiologists
United Kingdom
Fellowship
Clinical Oncology
2005
The Royal Colleges of Physicians
United Kingdom
Membership
2001
St Bartholomew's and The Royal London Hospitals Medical School
United Kingdom
MBBS
Medicine
1998
University of London
United Kingdom
BSc
Neuroscience & Basic Medical Sciences
Timeline
Place
Country
Position
Focus
Since 2014
Guys and St Thomas’ NHS Foundation Trust (GSTT)
United Kingdom
Consultant Clinical Oncologist
Gastrointestinal cancers
Timeline
Place
Organization
Position
-
United Kingdom
General Medical Council
Member
-
United Kingdom
British Medical Association
Member
-
United States
American Society for Radiation Oncology (ASTRO)
Member
-
Europe
European Society for Radiotherapy and Oncology (ESTRO)
Member
Timeline
Description
Collaboration
-
-
-
Timeline
Place
Award
Position
-
-
-
-

Clinical Experience.

General speciality (4)
Patients per year
Patients total
chemotherapy
0-50
-
immunotherapy
0-50
-
targeted therapy
0-50
-
general stomach tumour oncology
0-50
-
Tumor speciality (4)
Patients per year
Patients total
adenocarcinoma
0-50
-
gastrointestinal stromal tumours (gists)
0-50
-
mucosa associated lymphoid tissue (malt)
0-50
-
carcinoid tumours
0-50
-
General speciality (4)
Patients per year
Patients total
general esophageal tumour oncology
0-50
-
chemotherapy
0-50
-
immunotherapy
0-50
-
targeted therapy
0-50
-
Tumor speciality (2)
Patients per year
Patients total
adenocarcinoma
0-50
-
squamous cell carcinoma
0-50
-
General speciality (4)
Patients per year
Patients total
general colorectal tumour oncology
0-100
-
chemotherapy
0-50
-
immunotherapy
0-50
-
targeted therapy
0-50
-
Tumor speciality (4)
Patients per year
Patients total
adenocarcinoma
0-50
-
leiomyosarcomas
0-50
-
anal cancer
0-50
-
rectal cancer
0-50
-
Techniques (2)
Patients per year
Patients total
stereotactic radiotherapy (sbrt, sabr, cyberknife)
0-50
-
external beam radiotherapy (including imrt and igrt)
0-50
-

Skills & Endorsements.

General specialty
chemotherapy
immunotherapy
targeted therapy
General specialty
general esophageal tumour oncology
chemotherapy
targeted therapy
immunotherapy
General specialty
general colorectal tumour oncology
chemotherapy
immunotherapy
targeted therapy

Academic research.

2
Total articles
  • colorectal cancer - 2
  • chemotherapy - 2
2
colorectal cancer articles - Impact Factor
  • gastrointestinal tract - 2
  • oncology therapy - 2
Colorectal cancer treatment.

Colorectal cancer is the third most common malignancy in the developed countries, and about a quarter of people present with intestinal obstruction or perforation. Risk factors for colorectal cancer are mainly dietary and genetic. Overall 5-year survival is about 50%, with half of people having surgery experiencing recurrence of the disease.

Connections.

Map of connections

7
Scientific
co-authors
Our website unfortunately does not support your browser.<br/>Please click <a href="https://www.google.com/chrome/">here</a> to download and install new browser.
Supported browsers: Firefox, Chrome, Opera.